Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure

Citation
Abraham WT, Ponikowski P, Brueckmann M, et al. Eur J Heart Fail 2019;21:932–42.